Details

Autor(en) / Beteiligte

• Wang, Zi-Xian
• Cui, Chengxu
• Yao, Jun
• Zhang, Yanqiao
• Li, Mengxia
• Feng, Jifeng
• Yang, Shujun
• Fan, Yun
• Shi, Jianhua
• Zhang, Xizhi
• Shen, Lin
• Shu, Yongqian
• Wang, Cailian
• Dai, Tianyang
• Mao, Teng
• Chen, Long
• Guo, Zengqing
• Liu, Bo
• Pan, Hongming
• Cang, Shundong
• Jiang, Yi
• Wang, Junye
• Ye, Min
• Chen, Zhendong
• Jiang, Da
• Lin, Qin
• Ren, Wei
• Wang, Junsheng
• Wu, Lin
• Xu, Yong
• Miao, Zhanhui
• Sun, Meili
• Xie, Conghua
• Liu, Ying
• Wang, Qifeng
• Zhao, Lina
• Li, Qi
• Huang, Canhong
• Jiang, Ke
• Yang, Kunyu
• Li, Daojun
• Liu, Yunpeng
• Zhu, Zhitu
• Chen, Rixin
• Jia, Liqun
• Li, Wei
• Liao, Wangjun
• Liu, Hong-Xu
• Ma, Daiyuan
• Ma, Jie
• Qin, Yanru
• Shi, Zhihong
• Wei, Qichun
• Xiao, Ke
• Zhang, Yan
• Zhang, Ying
• Chen, Xin
• Dai, Guanghai
• He, Jianxing
• Li, Junhe
• Li, Guanghui
• Liu, Yong
• Liu, Zhihua
• Yuan, Xianglin
• Zhang, Junping
• Fu, Zhichao
• He, Yifu
• Ju, Fang
• Liu, Zheng
• Tang, Peng
• Wang, Tiejun
• Wang, Weibo
• Zhang, Jing
• Luo, Xianming
• Tang, Xiongwen
• May, Rena
• Feng, Hui
• Yao, Sheng
• Keegan, Patricia
• Xu, Rui-Hua
• Wang, Feng

Titel

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

Ist Teil von

• Cancer cell, 2022-03, Vol.40 (3), p.277-288.e3

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Platinum-based chemotherapy is the standard first-line treatment for advanced esophageal squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial.gov: NCT03829969), 514 patients with treatment-naïve advanced ESCC were randomized (1:1) to receive toripalimab or placebo in combination with paclitaxel plus cisplatin (TP) every 3 weeks for up to 6 cycles, followed by toripalimab or placebo maintenance. At the prespecified final analysis of progression-free survival (PFS), a significant improvement in PFS is observed for the toripalimab arm over the placebo arm (hazard ratio [HR] = 0.58; 95% CI, 0.46–0.74; p < 0.0001). The prespecified interim analysis of overall survival (OS) also reveals a significant OS improvement for patients treated with toripalimab plus TP over placebo plus TP (HR = 0.58; 95% CI, 0.43–0.78; p = 0.0004). The incidences of grade ≥3 treatment-emergent adverse events are similar between the two arms. Toripalimab plus TP significantly improves PFS and OS in patients with treatment-naïve, advanced ESCC, with a manageable safety profile. [Display omitted] •First-line toripalimab plus chemotherapy for esophageal squamous cell carcinoma•Toripalimab plus chemotherapy improves progression-free survival and overall survival•Toripalimab plus chemotherapy is efficacious irrespective of PD-L1 expression•Toripalimab plus chemotherapy shows a manageable safety profile Wang et al. demonstrate the efficacy and safety of toripalimab plus paclitaxel/cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma. As compared with paclitaxel/cisplatin alone, toripalimab plus paclitaxel/cisplatin extends progression-free survival and overall survival of the patients irrespective of PD-L1 expression.